131 related articles for article (PubMed ID: 25587694)
21. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
Freudenreich O; Cather C; Evins AE; Henderson DC; Goff DC
J Clin Psychiatry; 2004 Oct; 65(10):1372-6. PubMed ID: 15491241
[TBL] [Abstract][Full Text] [Related]
22. Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine.
Levin R; Calzavara MB; Santos CM; Medrano WA; Niigaki ST; Abílio VC
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1748-52. PubMed ID: 21693159
[TBL] [Abstract][Full Text] [Related]
23. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
24. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.
Hons J; Vasatova M; Cermakova E; Doubek P; Libiger J
J Psychiatr Res; 2012 Jun; 46(6):811-8. PubMed ID: 22502820
[TBL] [Abstract][Full Text] [Related]
25. Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia.
Thoma RJ; Hanlon FM; Miller GA; Huang M; Weisend MP; Sanchez FP; Waldorf VA; Jones A; Smith A; Formoso MJ; Cañive JM
J Int Neuropsychol Soc; 2006 Jan; 12(1):34-44. PubMed ID: 16433942
[TBL] [Abstract][Full Text] [Related]
26. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
[TBL] [Abstract][Full Text] [Related]
27. Short-term prospective comparison of prepulse inhibition between schizophrenic patients and healthy controls.
Preuss UW; Zimmermann J; Watzke S; Langosch J; Siafarikas N; Wong JW; Hamm A; Weike A
Pharmacopsychiatry; 2011 May; 44(3):102-8. PubMed ID: 21432751
[TBL] [Abstract][Full Text] [Related]
28. Various effects of antipsychotics on P50 sensory gating in Chinese schizophrenia patients: a meta-analysis.
Su L; Cai Y; Wang L; Shi S
Psychiatr Danub; 2012 Mar; 24(1):44-50. PubMed ID: 22447085
[TBL] [Abstract][Full Text] [Related]
29. Clozapine, cognition, and schizophrenia.
Launer M
Br J Psychiatry; 1993 Apr; 162():567-8. PubMed ID: 8481757
[No Abstract] [Full Text] [Related]
30. Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice.
Smucny J; Stevens KE; Tregellas JR
Pharmacol Biochem Behav; 2014 Mar; 118():22-9. PubMed ID: 24418217
[TBL] [Abstract][Full Text] [Related]
31. P50 sensory gating in multiplex schizophrenia families from a Pacific island isolate.
Myles-Worsley M
Am J Psychiatry; 2002 Dec; 159(12):2007-12. PubMed ID: 12450949
[TBL] [Abstract][Full Text] [Related]
32. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
[TBL] [Abstract][Full Text] [Related]
33. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.
Mattes JA
J Clin Psychiatry; 1989 Oct; 50(10):389-91. PubMed ID: 2571612
[TBL] [Abstract][Full Text] [Related]
34. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
[TBL] [Abstract][Full Text] [Related]
35. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.
Swerdlow NR; Light GA; Cadenhead KS; Sprock J; Hsieh MH; Braff DL
Arch Gen Psychiatry; 2006 Dec; 63(12):1325-35. PubMed ID: 17146007
[TBL] [Abstract][Full Text] [Related]
36. Sensory gating deficit in a subtype of chronic schizophrenic patients.
Ringel TM; Heidrich A; Jacob CP; Pfuhlmann B; Stoeber G; Fallgatter AJ
Psychiatry Res; 2004 Mar; 125(3):237-45. PubMed ID: 15051184
[TBL] [Abstract][Full Text] [Related]
37. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
38. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
[TBL] [Abstract][Full Text] [Related]
39. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.
Feifel D; Melendez G; Shilling PD
Neuropsychopharmacology; 2004 Apr; 29(4):731-8. PubMed ID: 14760394
[TBL] [Abstract][Full Text] [Related]
40. P50 gating at acute and post-acute phases of first-episode schizophrenia.
Devrim-Uçok M; Keskin-Ergen HY; Uçok A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1952-6. PubMed ID: 18929611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
